Shanghai, China – Aug. 11th, 2022. – The 2nd Roche Pan-Tumor Precision Medicine Innovation Forum was officially held at the Shanghai Roche Campus, where participants had discussions on recent progresses in this field.
At this forum, Amoy Diagnostics and Roche Pharma China reached a strategic cooperation to jointly promote the development of an open, cooperative and innovative medical and health ecosystem and provide patients with more accurate digital medical solutions. This coupled with the July 29th approval of Roche’s Rozlytrek (Entrectinib, a selective tyrosine kinase inhibitor to treat patients with NTRK-fusions positive solid tumours) in China will allow both companies to work jointly to establish a precise and treatment path and maximize the benefits for NTRK-fusion positive patients. Dr. Zhu Guanshan (VP of AmoyDx), was invited to participate in the forum and expressed his views on tumor-agnostic precision medicine and how to establish an effective patient diagnosis path.
Roche is a leading global biotechnology company headquartered in Switzerland with a history of over 125 years. Combining our unique advantages in the fields of pharmaceuticals and diagnostics, we are committed to advancing science and improving people’s lives through personalised healthcare. Established in 1994, as the first multinational pharmaceutical company setting up operations in Zhangjiang Hi-Tech Park, Roche Pharma China provides Chinese patients with breakthrough medicines in multiple key therapeutic areas, including oncology, infectious diseases and transplantation, immunology diseases and neuroscience. So far it has 25 medicines covering 8 therapeutic areas in China. Among multinational pharma companies, Roche takes the lead in building and upgrading a complete pharma value chain covering early research, late phase product development, manufacturing and commercialisation. Meanwhile, Roche continues to work with the government, medical institutions and NGOs to explore innovative modes of cooperation and benefit more Chinese patients through a series of influential and sustainable initiatives.
About Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685)
Amoy Diagnostics Co., Ltd. is a pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty products approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner of many pharmaceutical companies over the globe. For more information, please visit www.amoydiagnostics.com.